Late toxicities (LT) in patients affected by locally advanced (LA) oropharyngeal carcinoma (OPC) treated with definitive (chemo)radiotherapy (C)RT: Risk factors and pattern of adverse effects.

R Riccardo Gili (UO Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy) V Valentina Mirisola (Polistudium SRL, Milano, Italy) L Lisa F. Licitra (Fondazione IRCCS Istituto Nazionale dei Tumori & University of Milan, Milan, Italy) M Marta Maddalo (University of Brescia, Brescia, Italy) J Jon Cacicedo (Radiation Oncology Department, Hospital Universitario de Cruces/Biobizkaia Health Research Institute, Barakaldo, Spain) L Liliana Belgioia (Radiation Oncology Department, IRCCS Ospedale Policlinico San Martino, Genoa, Italy) A Almalina Bacigalupo (Radiation Oncology Policlinico San Martino IRCCS, Genova, Italy) A Almudena García Castaño (Hospital Universitario Marqués de Valdecilla, Santander, Spain) M Marc Oliva (Institut Català d’Oncologia L’Hospitalet, Institut d’Investigació Biomèdica de Bellvitge, Barcelona) P Pierluigi Bonomo (Azienda Ospedaliera Universitaria Careggi, Radiotherapy Unit, Florence, Italy) G Giuseppe Sanguineti (Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Roma, Italy) P Pierfrancesco Franco (University of Eastern Piedmont - Azienda Ospedaliero Universitaria “Maggiore della Carità”, Novara, Italy) A Athanassios Argiris (Thomas Jefferson University, Philadelphia, PA) A Amanda Psyrri (Section of Medical Oncology, Department of Internal Medicine, Attikon University Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece) E Ester Orlandi (Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy) P Paolo Bossi (Department of Biomedical Sciences, Humanitas University, Milan)

Abstract

e18111 Background: Treatment with CRT has a high burden of acute toxicities in OPCs patients, but data regarding LT are scarce. The more favourable prognosis of HPV-positive OPCs increases the importance to evaluate LT. Methods: We conducted a multinational, retrospective analysis of a consecutive series of LA OPCs treated with definitive RT with/without induction and/or concurrent CT, without any relapse or second primary cancer. We analysed the different patterns of LT in terms of type, number and grade (CTCAE v 5.0), as well as the baseline and treatment-related risk factors associated with LT development. We assessed with generalized linear model and binary logistic regression the impact of clinical and treatment related parameters on the number of LT and the development of at least one grade >2 toxicity. Two different models were created, one including the main clinical factors (alcohol consumption, smoking status, body-mass index, weight loss in past 6 months, stage, p16, p16 x smoking status, primary subsite, caregiver presence) and one considering the treatment-related variables (RT fractionation, type of concurrent CT, use of induction CT). Results: We analysed data from 275 patients (81% HPV-positive) treated with C(RT), with a median total dose of 70 Gy, at 14 European centres between 2007 and 2019. With a median follow-up of 6.4 years (range: 0.8–14.9 years), 201 (73%) experienced at least one treatment-related LT (median 2, range 1-5) of any grade. Overall, xerostomia and dysphagia were the most frequent LT, while weight loss and osteoradionecrosis were the most common ≥G3 toxicities. The incidence and severity of each LT are reported in Table 1. The n° of LT was significantly higher in pts who received conventional fractionation vs moderately acceleration or hyperfractionation, and for the primary subsite of soft palate. Conclusions: With the limitation of a retrospective analysis, xerostomia and dysphagia are the most frequent toxicities complained by the patients in the long term follow up of OPC treated with (C)RT. The number of LT is significantly higher in pts who received conventional fractionation, potentially related to the use of less conformal RT techniques, and for primary subsite in soft palate. This pattern of LT represents the benchmark to be compared with what obtained with de-escalation treatments. Pts with LT. Total n° of pts 275 (100%) N (%) N tox G1 N tox G2 N tox G3-4 N° of pts with any-grade of LT (%) 201 (73.1%) 135 (49.1%) 113 (41.1%) 19 (6.9%) Xerostomia 138 (50.1%) 88 (32.0%) 49 (17.8%) 1 (0.3%) Dysphagia 68 (24.7%) 49 (17.8%) 16 (5.8%) 3 (1.1%) Musculoskeletal fibrosis 63 (22.8%) 38 (13.8%) 24 (8.7%) 1 (0.3%) Hypothyroidism 45 (16.4%) 11 (4.0%) 34 (12.4%) 0 Weight loss 37 (13.4 %) 19 (6.9%) 10 (3.6%) 8 (2.9%) Osteoradionecrosis 21 (7.6%) 11 (4.0%) 3 (1.1%) 7 (2.5%) Pain 9 (3.2%) 6 (2.2%) 2 (0.7%) 1 (0.3%)

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (16)

R

Riccardo Gili

UO Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy

V

Valentina Mirisola

Polistudium SRL, Milano, Italy

L

Lisa F. Licitra

Fondazione IRCCS Istituto Nazionale dei Tumori & University of Milan, Milan, Italy

M

Marta Maddalo

University of Brescia, Brescia, Italy

J

Jon Cacicedo

Radiation Oncology Department, Hospital Universitario de Cruces/Biobizkaia Health Research Institute, Barakaldo, Spain

L

Liliana Belgioia

Radiation Oncology Department, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

A

Almalina Bacigalupo

Radiation Oncology Policlinico San Martino IRCCS, Genova, Italy

A

Almudena García Castaño

Hospital Universitario Marqués de Valdecilla, Santander, Spain

M

Marc Oliva

Institut Català d’Oncologia L’Hospitalet, Institut d’Investigació Biomèdica de Bellvitge, Barcelona

P

Pierluigi Bonomo

Azienda Ospedaliera Universitaria Careggi, Radiotherapy Unit, Florence, Italy

G

Giuseppe Sanguineti

Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Roma, Italy

P

Pierfrancesco Franco

University of Eastern Piedmont - Azienda Ospedaliero Universitaria “Maggiore della Carità”, Novara, Italy

A

Athanassios Argiris

Thomas Jefferson University, Philadelphia, PA

A

Amanda Psyrri

Section of Medical Oncology, Department of Internal Medicine, Attikon University Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

E

Ester Orlandi

Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy

P

Paolo Bossi

Department of Biomedical Sciences, Humanitas University, Milan